Bladder cancer: a protein blocker helped immunotherapy clear more tumors before surgery

Here is hopeful news about bladder cancer. Researchers found a way to help an immunotherapy drug work better against it, and the early results are strong.

In a new trial, patients with muscle-invasive bladder cancer got immunotherapy plus a drug called visugromab before surgery. About one in three had no cancer left when surgeons looked at the removed tissue. With immunotherapy alone, it was about one in twelve.

How the study worked

Thirty-one people with newly diagnosed muscle-invasive bladder cancer took part. All of them could not have, or chose not to have, the standard chemotherapy drug cisplatin. Each person received three rounds of the immunotherapy drug nivolumab, one every four weeks. Sixteen also got visugromab and fifteen got a placebo, and then everyone moved on to surgery. This was an early-stage phase 2a trial, with patients assigned in order rather than at random, published Oct. 24, 2026 in Nature Medicine.

What they found

The main goal was to see how many tumors disappeared or shrank. The combination did better on every measure of response.

That is six in ten tumors responding with the combination, compared with about one in seven or eight on scans with immunotherapy alone.

The treatment was also well tolerated. Nobody stopped treatment because of side effects, and no surgery was delayed. Serious side effects were no more common with visugromab than with placebo.

The researchers also saw that tumors responded best when they started out with more active immune cells called CD8+ T cells, the body’s own tumor fighters. The benefit did not depend on other markers they checked at the start.

Their conclusion: these findings support testing visugromab further in muscle-invasive bladder cancer.

What is GDF-15?

GDF-15 is a protein that muscle-invasive bladder tumors make in large amounts. Scientists recently identified it as a reason tumors can resist immunotherapy. Think of it as a shield around the tumor. Visugromab is an antibody that neutralizes GDF-15, so the immune system gets a clearer shot at the cancer.

This is why the result is encouraging. Immunotherapy before surgery is already an option for people who cannot take cisplatin. A partner drug that helps it work could make that option stronger.

What you can do today

This treatment is still in testing, so there is nothing to ask a pharmacy for yet. One simple thing is worth doing, though. If you have ever noticed blood in your urine, even once and even without pain, call your doctor’s office this week and book a visit to have it checked.